search
Back to results

The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension

Primary Purpose

Pulmonary Arterial Hypertension

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TPN171H
Sponsored by
Vigonvita Life Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Arterial Hypertension

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients who are able to signed the informed consent form ,understand and follow study plans and instructions; Patients aged 18 to 75; Patients with symptomatic PAH (Group1) with right heart catheterization results within the past 36 months (first category), a pulmonary vascular resistance (PVR) > 3 Wood, a mean pulmonary artery pressure (mPVP) ≥25 mmHg and a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg ; Patients have a current diagnosis of being in WHO functional class II or III; Targeted therapeutic drugs were not added, discontinued, or dosed within 4 weeks prior to baseline; 6.6-MWD between 100m &450m; 7.Patients who are willing to take proper contraceptive during the study and within 3 months after the study completed. Exclusion Criteria: All types of PH except subtypes of Group1 specified in the inclusion criteria; Patients who concomitant severe obstructive pulmonary disease(FEV1/FVC<0.5) ; Total lung volume<60% predicted; Systolic blood pressure below 90/60mmHg at screening; Left ventricular ejection fraction less than 45%, left ventricular short axis shortening rate less than 0.2; Lower limb diseases that affect the completion of 6-MWD testing; Subjects who received PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil, and avanafil) within 4 weeks before baseline CYP3A4 enzyme inducers (such as bosentan, aprepitant, barbiturates, carbamazepine, rifampicin, pioglitazone) or inhibitors (such as cimetidine, ciprofloxacin, boceprevir-d9,telaprevir, clarithromycin, nefazodone, and ritonavir) were taken within 2 months before the start of the trial, Regular or intermittent administration of nitrates (such as nitroglycerin, isosorbide nitrate,pentaerithrityl tetranitrate ) or any form of nitric oxide donor (including nicorandil, L-arginine) and α- Receptor blocking (such as phenoxybenzamine, prazosin, terazosin,tamsulosin) Subjects with a clear history of allergic diseases or who have previously stopped taking either aniracetam or tadalafil due to safety or tolerable reasons; Previous or current drug dependence, clear history of neurological or mental disorders, such as epilepsy, dementia, psychological or other emotional issues, may invalidate informed consent or limit the subject's ability to comply with the protocol; Acute or chronic organic diseases (excluding breathing difficulties) prevent subjects from completing the necessary testing items required in the study (especially the 6-minute walking distance test); Have a history of ophthalmic diseases, such as color vision abnormalities, retinitis pigmentosa, and macular degeneration; Malignant tumor patients; Moderate or severe liver function injury and/or blood ALT and AST exceeding 1.5 times the upper limit of normal values, and blood creatinine exceeding 1.5 times the upper limit of normal values; Pathogenic test for HIV positive; Positive test for hepatitis B or hepatitis C; Subjects suffering from acute infectious diseases; Suffered from infectious diseases recently (within 1 month); The subject has ischemic heart disease (defined as symptomatic, requiring anti angina treatment, or having experienced myocardial infarction within the past 3 years); Those who have experienced cerebrovascular events (such as transient ischemic attacks or strokes) within the past 3 months; Participated in any clinical trial within 3 months prior to taking the investigational drug; Pregnant or lactating women; The researchers believe that subjects who are not suitable to participate in this experiment due to other reasons.

Sites / Locations

  • Fu Zhu

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TPN171H

Arm Description

TPN171H is received 2.5mg QD for 2 consecutive weeks, then 5 mg QD for 14 consecutive weeks. If the dose is well-tolerated,TPN171H is up-titrated to 10mg QD , which will last for up to 2 years.

Outcomes

Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events
Q-T interval
Tmax
Cmax
AUC0~t
AUC0-∞
Terminal half-life (t 1/2)
Apparent distribution volume (Vd/F)
Clearance rate (CL/F)
Mean Residence Time(MRT)

Secondary Outcome Measures

6- Minute Walk Distance(6-MWD)
Cardiopulmonary function indicators reflecting the patient's physiological state
NT-proBNP
Heart failure evaluation indicators to evaluate the severity of heart failure;
The World Health Organization (WHO) functional class
Evaluate the severity of Pulmonary Arterial Hypertension symptoms at each time point before and after taking TPN171H
Borg dyspnea index
to evaluate the degree of difficulty breathing in subjects after a 6-minute walk test

Full Information

First Posted
June 21, 2023
Last Updated
October 11, 2023
Sponsor
Vigonvita Life Sciences
Collaborators
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT05948644
Brief Title
The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension
Official Title
Phase Ib Clinical Study on the Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in the Treatment of Pulmonary Arterial Hypertension (PAH) Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
April 8, 2019 (Actual)
Primary Completion Date
October 14, 2020 (Actual)
Study Completion Date
October 14, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vigonvita Life Sciences
Collaborators
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Exploring the safety, tolerability, and pharmacokinetic (PK) characteristics of oral TPN171H tablets in patients with Pulmonary Arterial Hypertension under continuous multiple administration conditions, providing a basis for determining the administration plan and recommended dosage in phase II clinical study.
Detailed Description
This study was divided into screening period, treatment period and medication follow-up period, and the treatment period included 3 cycles. First cycle: subjects receiving the test drug 2.5mg QD for 2 consecutive weeks, PK blood collection on Day 1 and Day 7, and the subjects discharged and returned to the hospital on Day 14 for medication monitoring blood collection, safety examination and efficacy assessment. Second cycle: up to 14 weeks; the second cycle is divided into monitoring and observation cycles; subjects who complete the first cycle and examinations enter the second cycle, with a 14 day monitoring period and 12 week observation period, with the second cycle dose of 5 mg QD, subjects received PK sampling on Day 7. Third cycle:The third cycle lasts for 8 days, subjects receive 10mg QD for 8 days; subjects received PK sampling on Day 7; subjects who completed an 8-day safety observation period on Day 8 without abnormal safety tests may be discharged. After discharge into the medication follow-up period. Medication follow-up period: up to 2 years; subjects entering the follow-up period will continue to take the dose of the last treatment period, return to hospital once every 12 weeks for safety examination and efficacy assessment until the subject intolerance or withdrawal from the study or expiration of 2 years (whichever occurs first).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Arterial Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TPN171H
Arm Type
Experimental
Arm Description
TPN171H is received 2.5mg QD for 2 consecutive weeks, then 5 mg QD for 14 consecutive weeks. If the dose is well-tolerated,TPN171H is up-titrated to 10mg QD , which will last for up to 2 years.
Intervention Type
Drug
Intervention Name(s)
TPN171H
Intervention Description
TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events
Time Frame
through study completion, an average of 2 years
Title
Q-T interval
Time Frame
through study completion, an average of 2 years
Title
Tmax
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
Cmax
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
AUC0~t
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
AUC0-∞
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
Terminal half-life (t 1/2)
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
Apparent distribution volume (Vd/F)
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
Clearance rate (CL/F)
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Title
Mean Residence Time(MRT)
Time Frame
From time zero up to 24 hours post-dose following oral administration of TPN171H
Secondary Outcome Measure Information:
Title
6- Minute Walk Distance(6-MWD)
Description
Cardiopulmonary function indicators reflecting the patient's physiological state
Time Frame
through study completion, an average of 2 years
Title
NT-proBNP
Description
Heart failure evaluation indicators to evaluate the severity of heart failure;
Time Frame
through study completion, an average of 2 years
Title
The World Health Organization (WHO) functional class
Description
Evaluate the severity of Pulmonary Arterial Hypertension symptoms at each time point before and after taking TPN171H
Time Frame
through study completion, an average of 2 years
Title
Borg dyspnea index
Description
to evaluate the degree of difficulty breathing in subjects after a 6-minute walk test
Time Frame
through study completion, an average of 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who are able to signed the informed consent form ,understand and follow study plans and instructions; Patients aged 18 to 75; Patients with symptomatic PAH (Group1) with right heart catheterization results within the past 36 months (first category), a pulmonary vascular resistance (PVR) > 3 Wood, a mean pulmonary artery pressure (mPVP) ≥25 mmHg and a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg ; Patients have a current diagnosis of being in WHO functional class II or III; Targeted therapeutic drugs were not added, discontinued, or dosed within 4 weeks prior to baseline; 6.6-MWD between 100m &450m; 7.Patients who are willing to take proper contraceptive during the study and within 3 months after the study completed. Exclusion Criteria: All types of PH except subtypes of Group1 specified in the inclusion criteria; Patients who concomitant severe obstructive pulmonary disease(FEV1/FVC<0.5) ; Total lung volume<60% predicted; Systolic blood pressure below 90/60mmHg at screening; Left ventricular ejection fraction less than 45%, left ventricular short axis shortening rate less than 0.2; Lower limb diseases that affect the completion of 6-MWD testing; Subjects who received PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil, and avanafil) within 4 weeks before baseline CYP3A4 enzyme inducers (such as bosentan, aprepitant, barbiturates, carbamazepine, rifampicin, pioglitazone) or inhibitors (such as cimetidine, ciprofloxacin, boceprevir-d9,telaprevir, clarithromycin, nefazodone, and ritonavir) were taken within 2 months before the start of the trial, Regular or intermittent administration of nitrates (such as nitroglycerin, isosorbide nitrate,pentaerithrityl tetranitrate ) or any form of nitric oxide donor (including nicorandil, L-arginine) and α- Receptor blocking (such as phenoxybenzamine, prazosin, terazosin,tamsulosin) Subjects with a clear history of allergic diseases or who have previously stopped taking either aniracetam or tadalafil due to safety or tolerable reasons; Previous or current drug dependence, clear history of neurological or mental disorders, such as epilepsy, dementia, psychological or other emotional issues, may invalidate informed consent or limit the subject's ability to comply with the protocol; Acute or chronic organic diseases (excluding breathing difficulties) prevent subjects from completing the necessary testing items required in the study (especially the 6-minute walking distance test); Have a history of ophthalmic diseases, such as color vision abnormalities, retinitis pigmentosa, and macular degeneration; Malignant tumor patients; Moderate or severe liver function injury and/or blood ALT and AST exceeding 1.5 times the upper limit of normal values, and blood creatinine exceeding 1.5 times the upper limit of normal values; Pathogenic test for HIV positive; Positive test for hepatitis B or hepatitis C; Subjects suffering from acute infectious diseases; Suffered from infectious diseases recently (within 1 month); The subject has ischemic heart disease (defined as symptomatic, requiring anti angina treatment, or having experienced myocardial infarction within the past 3 years); Those who have experienced cerebrovascular events (such as transient ischemic attacks or strokes) within the past 3 months; Participated in any clinical trial within 3 months prior to taking the investigational drug; Pregnant or lactating women; The researchers believe that subjects who are not suitable to participate in this experiment due to other reasons.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fu Zhu
Organizational Affiliation
Shanghai Xuhui Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fu Zhu
City
Shanghai
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension

We'll reach out to this number within 24 hrs